Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy.
نویسندگان
چکیده
OBJECTIVES To determine the risk factors for hyponatremia in patients with epilepsy treated with oxcarbazepine (OXC). METHODS Seventy-three adult patients with epilepsy aged older than 17 years who received OXC therapy were enrolled in this study. Patients who had hyponatremia due to any etiology before OXC therapy and patients receiving OXC therapy for nonepileptic disorders were excluded from this study. The baseline level of serum sodium of the patients was measured before the OXC therapy. During OXC therapy, serum sodium levels were measured at least once per 3 months. RESULTS The frequency of hyponatremia (Na+, ≤ 134 mEq/L) was 24.7% (n = 18) in patients with OXC therapy, and 8.2% (n = 6) of the patients had severe hyponatremia (Na+, ≤ 128 mEq/L). The degree of decline in serum sodium concentration was significantly negatively correlated with the dosage of OXC. An increase of 1 mg in the dosage of OXC increased the risk of hyponatremia by 0.2%. Moreover, increasing the number of combination antiepileptic drugs increased the risk of hyponatremia. CONCLUSIONS Higher dosages of OXC and the number of combination antiepileptic drugs may increase the risk of OXC-induced hyponatremia in patients with epilepsy. Most patients are asymptomatic, but if symptoms of hyponatremia, such as headache, general malaise, gait disturbance, and somnolence, are suspected, the serum sodium level should be measured; it may be necessary to decrease the OXC dose or to discontinue the drug.
منابع مشابه
Frequency of and risk factors for oxcarbazepine-induced severe and symptomatic hyponatremia
PURPOSE Hyponatremia is one of the most common adverse effects in patients treated with oxcarbazepine (OXC). Most patients with OXC-induced hyponatremia are asymptomatic, so the presence of severe or symptomatic hyponatremia, which requires electrolyte correction or discontinuation of OXC therapy, has more important clinically implications. However, data for OXC-induced severe and symptomatic h...
متن کاملAssessing long-term effects of eslicarbazepine acetate on lipid metabolism profile, sodium values and liver function tests.
INTRODUCTION Older dibenzazepines with a carboxamide substitution have been demonstrated to cause deleterious effects on lipid metabolism profile, as well as frequent hyponatremia. The aim of our study is to assess the effects of eslicarbazepine acetate, a novel AED, on lipid metabolism profile, sodium values and liver function tests, as well as to compare them with previous effects of carbamaz...
متن کاملCorrelation between Hyponatremia and High Risk Clinical and Echocardiographic Features in Patients with Acute Heat Failure
Background and purpose: Heart failure (HF) is characterized by decreased ability of the heart to provide sufficient blood flow or fill with the blood. Hyponatremia is the most commonly seen electrolyte abnormality in patients with heart failure that is associated with increased morbidity and mortality. The aim of this study was to assess the correlation between hyponatremia and high risk clinic...
متن کاملOxcarbazepine and adverse events: impact of age, dosage, metabolite serum concentrations and concomitant antiepileptic therapy.
The aim of this study was to investigate the relationships between oxcarbazepine (OXC) dosage, metabolite mono-hydroxy-derivative (MHD) serum concentrations, number of concomitant antiepileptic drugs, age and incidence of adverse events (AEs) in epileptic patients. A retrospective analysis was conducted of 414 consecutive epileptic patients on OXC alone or added-on to previous therapy. The samp...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical neuropharmacology
دوره 33 6 شماره
صفحات -
تاریخ انتشار 2010